Skip to main content
AAO-HNSF 2024 Annual Meeting & OTO EXPO Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Late-Breaking Scientific Oral Presentations

Otology/Neurotology

Session: Late-Breaking Scientific Orals: Otology and Neurotology

Tamoxifen Is a Risk Factor for Audiovestibular Symptoms and Sensorineural Hearing Loss

Sunday, September 29, 2024
2:42 PM – 2:48 PM EDT
Location: MBCC, 222
Disclosure(s):
Moaz Sinan, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Kenan A. Sinan, Other:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Brian M. Kellermeyer, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Introduction: Preclinical basic studies have demonstrated estrogen’s role in sex-linked differences in the biology of the inner ear. There is a paucity of research showing estrogen’s potential role in these differences in humans and its implications on audiovestibular symptoms. This multi-institutional retrospective chart review study aimed to use premenopausal breast cancer patients undergoing tamoxifen as an estrogen-depleted model to compare incidences of audiovestibular symptoms, potentially lending early evidence for estrogen’s role in sex-linked differences in humans.

Methods: This retrospective study used the multi-institutional TriNetx database to compare the incidence of audiovestibular symptoms and sensorineural hearing loss in premenopausal breast cancer patients who received tamoxifen during treatment with premenopausal breast cancer patients who did not receive tamoxifen during treatment. 1:1 propensity score matching was performed to control for confounding variables including antineoplastic agents received.

Results: The average age of patients after age of patients after matching was 42.5 (n = 13,441; stdev: 4.2). Receiving tamoxifen after treatment was associated with an increased risk of tinnitus (OR: 1.83; 95% CI (1.44-2.34)), sensorineural hearing loss (OR: 1.93; 95% CI (1.4-2.67)), need for audiologic function testing (OR 2.07; 95% CI (1.62-2.68)), and vestibular dysfunction (OR: 2.06; 95% CI (1.49-2.85)). Tamoxifen use was not significantly associated with an increased risk of hearing aid use (OR:1; 95% CI (0.42-2.4)) or cochlear implantation.

Conclusions: Tamoxifen is a risk factor for audiovestibular symptoms and sensorineural hearing loss in premenopausal women with breast cancer. This suggests a need for more research studies evaluating estrogen’s role in sex-based differences of the inner ear and subsequently its role in clinical pathologies including vestibular migraines.

    Presenting Author(s)

  • Moaz Sinan, MD

    Resident Trainee
    West Virginia University School of Medicine
    West Bloomfield, MI, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

    • Author(s)

  • MB

    Mustafa G. Bulbul, MD

    Resident
    West Virginia University
    Morgantown, WV, United States

    Disclosure information not submitted.

  • NS

    Noah E. Shaikh, MD

    Resident
    West Virginia University
    Morgantown, WV, United States

    Disclosure information not submitted.

  • KS

    Kenan A. Sinan

    Medical Student
    Wayne State University School of Medicine
    West Bloomfield, Michigan, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

    • Senior Author(s)

  • BK

    Brian M. Kellermeyer, MD

    Associate Professor, Residency Program Director
    WVU - Dept of OTO
    Morgantown, West Virginia, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.


Back to Top